CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
Gemcitabine +3 moredrug
Likely dose
Gemcitabine 1000mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00350142
NCT00350142Phase 2Completed
CompareCT.gov

Phase II Study to Evaluate the Efficacy of Trilogy Stereotactic Radiosurgery for Pancreatic Cancer

Albert Koong·interventional·Posted Jul 10, 2006·Updated Feb 14, 2017

In Brief

A Phase 2 clinical trial evaluating Stereotactic Body Radiotherapy, Gemcitabine, and 2 other interventions for Pancreatic Cancer. Completed, enrolled 20 participants across 1 site.

Detailed Summary

This study will assess the efficacy of treating locally advanced pancreatic cancer using Stereotactic Body Radiotherapy (using Trilogy) and Gemcitabine

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 10, 2006
Enrollment StartApr 1, 2006
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 20.0 years ago

Interventions

Stereotactic Body Radiotherapyradiation

Stereotactic Body Radiotherapy will be performed using Trilogy Linear Accelerator

Gemcitabinedrug

Weekly Gemcitabine will be administered at 1000mg/m2 over 100 minutes

4D pancreatic protocol CT scanother

Patients will undergo this imaging procedure prior to treatment for planning purposes.

FDG PET scanradiation

Patients will have this imaging procedure along with a CT scan to map the tumor and facilitate treatment planning.